Best of heart failure

45 contemporary clinical practice (featuring drugs) who can be titrated to target beta- be in the range of 20 to 40% [ 31 ]. Hyperpolarization-activated c nucleotide-gated channel inh Hyperpolarization-activated cyclic nuc channels play important roles both in t neuronal excitability. HCN channels o tion voltage, permeate to potassium and an inward current, which is modulated adenosine monophosphate (cAMP). In thologies, dysfunctional HCN channels to be a direct cause of rhythm disorder of-function in atrial fibrillation, ventric failure might help enhance ectopic elect mote arrhythmogenesis [ 32 ]. Novel compounds with enhanced selec channel isoforms are being studied as p new drug development. Ivabradine is t inhibitor being clinically approved in 20 chronic stable angina pectoris and HF. Iv HR-reducing drug that works only in si inhibiting the so-called funny current (I through the blockade of the I f channel (Fi The current across the I f channel is a um current, and the I f channel is activate and regulated by direct binding of cAM rectly modulates the HCN channel by in of channel opening during diastole; in t depolarization slope becomes steeper an Fig. 1 The mechanism of action of ivabradine. Ivabradine within SA node selectively blocks the HCN channel, inhibits the If current, slows diastolic depolarization, and lowers heart rate. HCN channel hyperpolarization-activated cyclic nucleotide-gated; If current inward flow of positively charged ions that initiates the spontaneous diastolic depolarization phase, modulating heart rate; SA node sinoatrial node Heart Fail Rev (2018) 23:517 – 525 recommended to be in reach the target 97/10 should not be given c to risk for angioedema, stopped for 36 h bef patients with eGFR < impairment, the starti daily and ARNI is not hepatic impairment [ 3 With the results of t ommendations have b HF Guidelines. First, ACE inhibitors or an strategy of RAS inhibit or ARB or ARNI. T strategy of inhibition of evidence: A), or A (level of evidence: B – beta-blockers and aldo is recommended for p morbidity and mortalit In the 2017 Focuse with chronic symptom tolerate an ACE inhibit recommended to furth 36 •• ]. In those patie switched to ARNI fro to note that ARNI sho with ACE inhibitors or inhibitor due to angio should not be administ edema [ 1 •• ]. In the stu inhibition, blacks and angioedema [ 35 ]. It is be educated about rec ma and to alert health scription of ACE inhi In a phase II trial i served ejection fractio greater extent than di tolerated [ 39 ]. The eff compensated HF, in a IV symptoms, or in p time and is being teste Ivabradine Ivabradine is a specifi channel. If ion channel in spontaneously activ node, the AV node, an is a mixed Na/K curre at voltages in the dia 39 Page 4 of 9 15. Katz AM (1990) Cardiomyopathy of overload. A major determi- nant of prognosis in congestive heart failure. N Engl J Med 322: 100 – 110 16. Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M (2013) Heart failure biomarkers in patients with dilated cardiomyopathy. Int J Cardiol 168(3):2404 – 2410 17. Gupta S, Figueredo VM (2014) Tachycardiamediatedcardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 172(1):40 – 46 18. Anker MS, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, Anker SD, Landmesser U, Haverkamp W, von Haehling S (2016) Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. Eur J Heart Fail 18(12):1524 – 1534 19. Teodorescu C, Reinier K, Uy-Evanado A, Gunson K, Jui J, Chugh SS (2013) Resting heart rate and risk of sudden cardiac death in the general population: influence of left ventricular systolic dysfunction and heart rate-modulating drugs. Heart Rhythm 10(8):1153 – 1158 20. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372(9641):817 – 821 21. Logeart D, Seronde MF, Degroote P et al (2012) Raised heart rate at dis charge after acute heart failure is an independent predictor of one-year mortality [abstract P2775]. Eur Heart J 33(suppl):485 22. Gillman MW, Kannel WB, Belanger A, D ’ Agostino RB (1993) Influence of heart rate on mortality among persons with hyperten- sion: the Framingham study. Am Heart J 125:1148 – 1154 23. Chang M, Havlik RJ, Corti MC, Chaves PH, Fried LP, Guralnik JM (2003) Relation of heart rate at rest and mortality in the Women ’ s Health and Aging Study. Am J Cardiol 92:1294 – 1299 24. Kristal-Boneh E, Silber H, Harari G, Froom P (2000) The associa- tion of resting heart rate with cardiovascular, cancer and allcause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 21:116 – 124 25. Fujita B, Franz M, Goebel B, Fritzenwanger M, Figulla HR, Kuethe F, Ferrari M, Jung C (2012) Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardio- myopathy. Clin Res Cardiol 101:701 – 707 26. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators (2002) Systolic Hypertension in Europe (Syst-Eur) Trial Investigators (2002) Predictive value of clinic and ambulatory heart rate for mor- tality in elderly subjects with systolic hypertension. Arch Intern Med 162:2313 – 2321 27. Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159:585 – 592 28. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150:784 – 794 29. Pourdjabbar A, Dwivedi G, Haddad R, Saikali A, Mielniczuk L, Haddad H (2015) Heart rate control in patients with left ventricular systolic dysfunction and heart failure. Int J Cardiol 184:276 – 277 30. Fu M, Ahrenmark U, Berglund S, All investigators of the HR-HF study et al (2017) Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). Clin Res Cardiol 106:960 – 973. https://doi.org/10.1007/s00392-017-1146-6 31. Swedberg K, Komajda M, Böhm BJ, RobertsonM, Tavazzi L, Ford I (2012) For the SHIFT investigators effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study. J Am Coll Cardiol 59(22):1938 – 1945 32. Sartiani L, Mannaioni G, Masi A, Novella Romanelli M, Cerbai E (2017) The hyperpolarization-activated cyclic nucleotide-gated channels: from biophysics to pharmacology of a unique family f ion channels. Pharmacol Rev 69(4):354 – 395 33. Verkek AO (2009) Pacemaker activity of the human sinoatrial node: role of the hyperpolarization-activated current, If. Int JCardiol 132: 318 – 336 34. Di Francesco D (2007) The funny curr nt. Cellul r basis for th control of heart rate. Drugs 67(Suppl 2):15 – 24 35. Di Francesco D (1991) Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 351:145 – 147 36. Camm AJ, Lau CP (2003) Electrophysiological effects of a single intravenous administration of ivabr dine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4:83 – 89 37. Manz M, Reuter M, Lauck G, Omran H, Jung W (2003) A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100:149 – 155 38. Ferrari R (2014) Ivabradine: heart rate and left ventricular function. Cardiology 128:226 – 230 39. Vilaine JP (2006) The discovery of the selective If current inhibitor ivabradine. A new therapeutic approach to ischemic disease. Pharmacol Res 53:424 – 434 40. Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D (2007) (220) Heart rate reduction via selective ‘ funny ’ channel blockers. Curr Opin Pharmacol 7:208 – 213 41. Nakada N (2016) Investigation of metabolite profile of YM758, a novel If channel inhibitor. Drugs R D 16(2):205 42. Umehara KI, Nakamata T, Suzuki K, Noguchi K, Usui T, Kamimura H (2008) Pharmacokinetics of YK754, a novel If chan- nel inhibitor in rats, dogs and humans. Eur J Drug Metab Pharmacokinet 33:117 – 127 43. Owczarek J, Jasi ń ska M, Dro ż d ż J, Orszulak-Michalak D (2012) Concomitant administration of simvastatin with ivabradine in con- trast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats. Arch Med Sci 8(3):549 – 554 44. Tardiff JC (2005) Efficacy of ivabradine, a new selectiv If inhibi- tor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529 – 2536 45. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial. Lancet 372:807 – 816 46. Borer JS, Deedwania PC, Kim JB, Böhm M (2016) Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. Am J Cardiol 118(12):1948 – 1953 47. Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U (2012) Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol 101:365 – 373 48. Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treat- ment of stable angina pectoris in octogenarians. Clin Res Cardiol 100:121 – 128 49. Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99:665 – 672 50. M V, Cice G, Caminiti G et al (2011) Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol 151(2): 218 – 224 524 Heart Fail Rev (2018) 23:517 – 525